By 1969, the US bioweapons program had developed weapons of a “nuclear equivalence,” according to David Franz, who, for twenty-three years, served as commander of the US Army Medical Research Institute of Infectious Diseases (USAMRIID).4 The principal limitation, Franz acknowledged, was the difficulty of managing bioweapons so as to prevent accidental escape. Ironically, Franz would later play a key role in the Pentagon/Fauci gain-of-function programs leading up to the COVID-19 pandemic.
